:) :) So much more to come in how we use digital health tools *intentionally* to improve patient engagement, autonomy, and outcomes. Thanks to @gynoncjnls for publishing our work!!
Today is #WorldOvarianCancerDay! According to Globocan, by 2040, the number of women around the world diagnosed with #OvarianCancer will rise almost 42%. This disease is a global concern, and we need to unite to tackle this disease on all fronts.
#NoWomanLeftBehind#WOCD2023
New #TeamOvary scrub cap, matching Wu Tang socks, and Dr. Olga Filippova’s LAST DAY ever operating with @dchimd after working with him closely for the last 6 years! Bittersweet feelings today on Team Ovary but excited to see her bright future! #wegowherethecancergoes
So powerful- for all the working moms and dads with guilt. “Go Mommy Go” “My Mom cured cancer, did yours?” Dr Carol Aghajanian congrats on #GY-018 & for raising 2 incredible boys! @SGO_org @GOG @ASCO @IGCSociety @Perlmutter_CC
Late breaking at #SGOMtg: In patients with advanced or recurrent endometrial cancer, the addition of pembrolizumab to standard chemotherapy resulted in significantly longer progression-free survival than chemotherapy alone. https://t.co/dTyV1zTO0I
#SGOMtg: A randomized trial compared standard chemotherapy plus dostarlimab or placebo. Patients with mismatch repair–deficient tumors had 2-year progression-free survival of 61.4% with dostarlimab and 15.7% with placebo. Read full results of RUBY trial: https://t.co/w5JgJbEcoq
People with germline BRCA 1 or 2 mutations are at an increased risk of cancer and benefit from annual breast MRIs. At #SGO23, @sushmitabg outlined insurance denials as a barrier to screening and proposed revisions to insurance guidelines for those at high risk. @SGO_org
And just so inspired by the #PatientsPurposeProgress presented at this #SGOMtg and can’t wait to continue to be a part of this amazing field and take care of our amazing patients!!